Chapter 6 | Interpregnancy interval, folate, and birth weight 
Abstract

Background
Maternal folate depletion has been proposed as primary explanation for the excess risk of fetal growth restriction associated with short interpregnancy intervals.
Objective
To evaluate the folate depletion hypothesis in a community-based cohort of pregnant women.
Design
Using a subsample of the cohort (multiparous participants who delivered a singleton liveborn infant, n = 3153), we investigated the relationship between increasing interpregnancy interval (1-24 months, natural log transformation) and birth weight and small-for-gestational-age (SGA) risk in three strata of maternal periconceptional folic acid use: "nonuse", "late use" (start aft er conception), and "early use" (start before conception).
Results
Each unit increase in the interpregnancy interval on the natural log (ln) scale was associated with a birth weight increase of 63.1 g (SE 20.3, P = 0.002). Th is relationship was mitigated by folic acid use: the increase in birth weight per unit increase in ln(interpregnancy interval) was 165.2 (39.6) g for nonuse (P < 0.001), 33.5 (35.6) g for late use (P = 0.347), and −5.8 (33.6) g for early use (P = 0.861). Th e birth weight diff erences were directly translated into SGA risk. Odds ratios per unit increase in ln(interpregnancy interval) were signifi cant for the group in total (0.61; 95% CI: 0.46, 0.82) and for nonuse (0.38; 95% CI: 0.24, 0.60), and nonsignifi cant for late use (0.83; 95% CI: 0.48, 1.44) and for early use (1.28; 95% CI: 0.58, 2.84).
Conclusion
Folate depletion apparently contributes to the excess risk of fetal growth restriction associated with short interpregnancy intervals. As a preventive option, postnatal supplementation may be benefi cial, but confi rmation is needed.
Introduction
Several studies have reported increased risks of the adverse pregnancy outcomes low birth weight (LBW) and small for gestational age (SGA) aft er short interpregnancy intervals. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Yet, a general explanation for these excess risks, in a recent meta-analysis estimated to be just over 60% for LBW and 25% for SGA, 14 is still lacking. Some authors have attributed the higher risk of poor pregnancy outcomes to factors associated with -rather than causally related to -short interpregnancy intervals, such as maternal sociodemographic characteristics and lifestyle. [15] [16] [17] However, accumulating evidence from the studies that did extensively control for such risk factors [3] [4] [5] 7, [10] [11] [12] suggests that the adverse outcomes are not merely the results of confounding. A plausible, more causal, hypothesis that has been put forward to explain the excess risk is the nutritional depletion hypothesis, 18, 19 which states that women with closely spaced births have insuffi cient time to restore the nutritional reserves needed to support fetal growth and development in the subsequent pregnancy. Folate depletion in particular has been proposed as the nutritional factor that contributes most to the risk of fetal growth restriction. 20 During pregnancy, folate is mobilized from maternal stores to meet the increasing demands of mother and child. If dietary supply is low, concentrations begin to decline from the fi ft h month of pregnancy onwards, and continue to decline until several weeks aft er delivery. 21, 22 As repletion of stores may then take several months, 22 mothers conceiving a subsequent child within these fi rst months postpartum are at increased risk of folate defi ciency. As a consequence, their off spring may be at higher risk of intrauterine growth restriction and LBW, which have been associated with both low folate and high homocysteine concentrations (as marker for folate defi ciency) 23 before. [24] [25] [26] [27] [28] [29] In the present study, we evaluate the folate depletion hypothesis as an explanation for short interval-associated adverse outcomes, by examining in diff erent strata of folic acid supplement use the relationship of interpregnancy interval with infant birth weight and SGA risk at term. If the hypothesis is true, we expect to (a) observe an increased risk of fetal growth restriction (i.e., lower birth weight and higher SGA risk) at short intervals, which diminish with increasing interval length, and (b) fi nd a mitigating infl uence of folic acid supplement use on these risks. More specifi cally, lower birth weight and higher SGA risk are particularly expected among nonusers, who are at highest risk of folate depletion, and not, or to a lesser extent among early (start before conception) or late (start aft er conception) users. If our fi ndings corroborate the hypothesis, this could open new avenues for the prevention of adverse pregnancy outcomes among women conceiving their second or subsequent child, in particular those who become pregnant shortly aft er their previous pregnancy. 
Subjects and methods
Study population and design
Th is study is part of the Amsterdam Born Children and their Development (ABCD) study, a prospective community-based cohort study that examines the relationship between maternal lifestyle and psychosocial conditions during pregnancy and the child's health at birth as well as in later life. Th e design of the study has been described to a large extent previously. 30 In short, between January 2003 and March 2004, pregnant women living in Amsterdam were invited to enroll in the ABCD study during their fi rst antenatal visit to the obstetric care provider (around the 12th week of gestation), and requested to complete a questionnaire, covering sociodemographic data, obstetric history, lifestyle, dietary habits, and psychosocial factors. Th e questionnaire was available in Dutch as well as in English, Turkish, and Arabic for immigrant women. In total, 8266 of the 12 373 pregnant women invited to participate returned the pregnancy questionnaire (response rate 67%). Of this group, 7738 women gave birth to a viable singleton infant for whom information on birth weight and pregnancy duration was available. For the present study we excluded all women with preterm deliveries (n = 410) as well as all women with fi rst-time deliveries (n = 3993). Th e total number available for analyses was 3335.
Th e study was approved by the Medical Ethical Committees of the participating hospitals and the Registration Committee of Amsterdam. All participating women gave written consent.
Measurements
Primary outcome variables for the present study were birth weight (continuous in grams) and SGA (yes, no) at term, with SGA defi ned as a birth weight below the 10th percentile for gestational age on the basis of sex-and parity-specifi c standards from the Netherlands Perinatal Registry (data available from the authors upon request). Data on date of delivery, infant sex, birth weight, and gestational age [ultrasound-based or, if unavailable (<10%), on the timing of the last menstrual period] as recorded by the obstetric care providers were obtained through the Youth Health Department at the Municipal Health Service in Amsterdam.
Interpregnancy interval was calculated as the number of months between date of delivery and date of preceding birth, diminished by pregnancy duration. Th e latter was defi ned by the gestational age at the time of delivery in days. Th e use of folic acid supplements was assessed by the question: "Have you taken folic acid, either as a single supplement or as part of a multivitamin supplement, before or during your pregnancy?". As the general recommendation is to start taking supplements at least four weeks before conception, 31 women were also asked to indicate when they had started taking supplements: (a) before conception or (b) aft er conception. Women who took folic acid supplements and had started before conception were classifi ed as "early users" of folic acid. Th ose who took folic acid supplements but had started aft er conception were classifi ed as "late users", and those who did not use folic acid supplements at all as "nonusers".
A number of maternal physiologic, obstetric, lifestyle, and sociodemographic characteristics obtained via the questionnaire were considered covariables. Physiologic and obstetric variables included age (<25, 25-34, ≥35 years), parity (1, 2, ≥3), height (cm), pregnancy intention as measured by questioning whether the respondent had wanted to become pregnant (yes, no), and start of prenatal care (<18 weeks, 18-23, ≥24 weeks). Lifestyle variables included alcohol consumption before or during early pregnancy (self-reported previous week's behavior and behavioral change since pregnancy, recoded into: "no", "yes, but not since pregnancy", "yes, also during pregnancy"), smoking habits before and during early pregnancy (self-reported previous week's behavior and behavioral change since pregnancy, recoded into: "no", "yes, but not since pregnancy", "yes, also during pregnancy"), pregravid body mass index (BMI, kg/m 2 ) based on self-reported height and weight, and psychosocial stress (presence of 0, 1, or ≥2 stressors). A random imputation procedure using linear regression analysis was used to complete missing data on height (3.8% missing) or weight (9.9% missing). 32 Psychosocial stressors were measured by validated Dutch versions of internationally accepted questionnaires and included depression, 33 general anxiety, 34 pregnancy-related anxiety, 35 parenting stress, 36 and work stress. 37 Th resholds for nonnormal scores, assuming a representative group of pregnant women, were by design chosen at the 90th percentile. Lastly, sociodemographic factors were cohabitant status (living together with partner or living alone), educational attainment aft er primary school (<6, 6-10, ≥11 years), and country of birth (the Netherlands, Surinam, Turkey, Morocco, other non-Western country, other Western country).
Statistical analysis
Of the 3335 women included, 75 women did not provide information on interpregnancy interval (n = 55) or folic acid supplement use (n = 20), while 107 women had one or more missing values on the above-mentioned covariables (missing rate per item ≤2%). Aft er exclusion of these respondents the fi nal sample for analysis was 3153.
Aft er a descriptive analysis of the infant and maternal characteristics, we performed univariate and multivariate regression analyses to estimate the association of interpregnancy interval as categorical variable with term birth weight (linear regression) and SGA (logistic regression). For interpregnancy interval, previously defi ned categories were used: 0-5, 6-11, 12-17, 18-23, 24-59, and ≥60 months.
14 Models were adjusted for above-mentioned maternal physiologic, obstetric, lifestyle, and sociodemographic characteristics (see Measurements). For birth weight as outcome variable, adjustments were also made for infant sex and gestational age. Th ese analyses allowed us to evaluate the actual presence of an association in our population and relate our fi ndings to previous studies.
To specifi cally test the folate depletion hypothesis, we performed predefi ned multivariate regression analysis including the natural log transformation of the interpregnancy interval as continuous variable. First, multivariate models were fi t to describe the relation between increasing length of interpregnancy interval (1 to 24 months) and birth weight (linear regression model) or SGA (logistic regression model). Although both short and long interpregnancy intervals have previously been associated with adverse outcomes, the latter association is not expected to be infl uenced by folate depletion; 14, 20 therefore, long intervals were excluded for this part of the analysis. Th e particular cutoff of 24 months and natural log transformation were chosen because the risks associated with short intervals have been shown to normalize within this time frame, following an inverse J-shaped pattern (aft er an initial steep decline in risk, a gradual leveling off with increasing interval length).
3,6,9-14 Second, stratifi ed analysis using the previously defi ned models for birth weight and SGA was performed to evaluate the mitigating infl uence of folic acid supplement use. Strata were no use, late use, and early use (see Measurements). Th e hypothesized mitigating infl uence of folic acid use was subsequently statistically tested by including both supplement use and interaction terms for supplement use and interpregnancy interval in the models (test for eff ect modifi cation).
Associations were considered statistically signifi cant at P < 0.05. All analyses were conducted in SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of the mother-infant pairs included (n = 3153) are presented in Table 6 .1. Mean infant birth weight (± SD) was 3579 (± 497) g, mean gestational age at birth 40.0 (± 1.2) wk. In total, 12.5% of the infants were born SGA. Sixty-four percent of the mothers had used folic acid supplements during pregnancy; 29% had started taking these supplements aft er conception, and 35% had already started taking these supplements before conception.
Less than 4% of the women (n = 124) became pregnant within 6 months aft er the previous delivery, whereas 16% of the women (n = 513) had intervals of 5 years or longer ( Table  6. 2). In univariate analyses, both short (<6 months) and long (24-59, ≥60 months) interval categories reduced birth weight, with a corresponding increase in SGA risk for intervals <6 months and ≥60 months. Aft er adjustment for relevant maternal and infant characteristics, these associations persisted for the short interval category (mean estimated diff erence in birth weight −142.1 g, SE 44.1; odds ratio (OR) for SGA 2.12, 95% CI 1.23, 3.65; reference 18-23 months), but not for the 24-59 month interval category. Intervals exceeding 60 months were no longer associated with SGA risk, but remained negatively associated with birth weight (−66.6 g, SE 30.8; reference 18-23 months). Th e results of the regression analyses describing the relationship of increasing interpregnancy interval (1-24 months) with birth weight and SGA in our cohort are presented in Figure  6 .1. Each unit increase in the interpregnancy interval expressed on a natural log scale was associated with an increase in birth weight of 63. In line with the hypothesis, we observed a mitigating eff ect of folic acid supplement use on the relationship of interpregnancy interval with birth weight (Figure 6 .2) and SGA ( Figure  6.3) . Stratifi ed analysis showed that in both early and late supplement users the association between interval and birth weight or SGA no longer existed; the change in birth weight per unit increase in ln(interpregnancy interval) was −5.9 g (SE 33.6) for early users and 33. Th e interaction model confi rmed that the eff ect modifi cation as observed in the stratifi ed analysis was signifi cant for both birth weight (P = 0.001) and SGA (P = 0.008). 
Estimates for birth weight were derived from a continuous multivariate linear regression model with birth weight as dependent and ln(interpregnancy interval) as primary independent variable; odds ratios for SGA were derived from a multivariate logistic regression model with SGA as dependent and ln(interpregnancy interval) as primary independent variable. In both models, adjustments were made for a predefi ned set of covariables (see footnote
Estimates for birth weight were derived from a multivariate linear regression model with birth weight as dependent and ln(interpregnancy interval) as primary independent variable. Adjustments were made for a predefi ned set of covariables (see footnote Table 6.2). Analyses were stratifi ed for folic acid supplement use: nonuse (n = 414), late use (n = 537), and early use (n = 635). For presentation purposes monthly intervals were combined in three-
Discussion
Th e results of this large, prospective cohort study not only confi rm previous research showing a negative association between short interpregnancy intervals and fetal growth, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] but moreover support the explanatory hypothesis of folate depletion. 20 Among those most at risk of folate depletion -the nonusers of folic acid supplements -we observed an increased risk of fetal growth restriction (as refl ected by a lower mean birth weight and higher SGA risk) at short interpregnancy intervals, which diminished with increasing interval length. In contrast, no signifi cant interval-associated decrease in birth weight or increase in SGA risk was observed among supplement users. Th ese observations imply that the adverse eff ects of interpregnancy intervals shorter than 6 months could be preventable by the use of folic acid supplements in the period between the consecutive pregnancies. Following the hypothesis, the mitigating infl uence of folic acid supplementation was expected to be dose-dependent. Indeed, we observed the interval-associated risks of lower birth weight and SGA among late users (i.e., start aft er conception) to be intermediate between the interval-associated risks among nonusers and early users (i.e., start before conception). Th e biological plausibility of this dose-dependency lends further credibility to a true causal role of folate depletion in the association between interpregnancy interval and adverse pregnancy outcomes. Folate has a fundamental role in the process of cell division because of its role in DNA synthesis. Particularly during pregnancy -a time of tissue growth and sustained cell division -the need for folate increases. 38 Where low maternal folate concentrations may negatively infl uence fetal growth and development, folate supplementation to restore folate status may counterbalance these eff ects. Th e largest reduction in risk may thus be expected from supplementation starting prior to conception, ensuring adequate folate status during the critical stage of embryonic development. 20 Indeed, previous studies have shown a preventive eff ect of higher folate intakes on adverse pregnancy outcomes particularly in women at high risk of folate defi ciency. Given the unavoidable nonexperimental setting of our study, alternative explanations for our observations should be considered. We cannot exclude the possibility that our results are explained by maternal characteristics associated with supplement use (e.g., being more healthconscious), or more specifi cally by the concurrent intake of other micronutrients relevant to fetal growth. However, most micronutrients return to normal fairly rapid aft er delivery; 22, 41 in addition, from the available follow-up information, which included a retrospective assessment of the sort of supplements used (single supplements vs. multivitamin supplements; available for 1509 of the 2029 supplement users in this study) it can be concluded that the majority were single users only (65%). In this context, we assume the role of nutrients other than folate to be minor.
A strength of our study is the focus on term birth weight and SGA in parallel. SGA is the most important outcome in terms of clinical relevance, but the use of birth weight as continuous measure and the planned exclusion of preterm births allowed us to also capture the physiological evidence on overall weight eff ects of folate, without the distorting eff ect of preterm delivery. 42 Th e mechanism through which folate depletion aff ects preterm delivery is likely to diff er from the mechanism through which it aff ects birth weight, further justifying this separation. Th e observed corresponding eff ects of interpregnancy interval on term birth weight and SGA in this cohort were adjusted for a large set of simultaneously measured risk factors relevant to fetal growth in the index pregnancy. However, the design of our study limited our ability to measure factors related to the preceding pregnancy, such as the outcome of pregnancy and maternal breastfeeding. Breastfeeding practices may interact with the association between folate depletion and interpregnancy interval, as women who breast-feed are more at risk of depletion. 20 Th e outcome of the preceding pregnancy has been shown to relate to the outcome of subsequent pregnancies. 43 However, this correlation may refl ect one or more persisting factors that aff ect all infants in a sibship, such as smoking. 44 To the extent that these factors were known in our cohort, they were adjusted for in our analyses. In addition, in previous studies that did control for the outcome of the preceding pregnancy, the adjustment did not aff ect the J-shaped relationship between interpregnancy interval and risk of fetal growth restriction. [10] [11] [12] Another limitation related to the design of our study may be the measurement of folic acid supplement use, which was self-reported. One could assume that over-reporting of this social desirable healthy behavior infl uenced our observations. However, self-administered questionnaires have been shown to validly measure folic acid use; 45 if any over-reporting would be present, this might imply that our estimates are too conservative.
Th roughout the world, the use of folic acid supplements as proven measure to prevent birth defects has induced specifi c public health policies to promote folic acid intake. 46, 47 While the issue presented here is relevant for the majority of countries that have supplementation policies similar to those in the Netherlands, it is more diffi cult to generalize our results to countries where supplementation policies are integrated with the population-wide fortifi cation of fl our, such as in the Unites States. 46 However, recent evidence from the US has shown the persistent need for supplementation, as aft er an initial rise folate concentrations in women of childbearing age have declined again in the recent years. 48 while low levels are still common among ethnic minority groups, who also are at risk for short interpregnancy intervals. [4] [5] [6] [7] [9] [10] [11] [12] In summary, this large-scale prospective cohort study suggests that folate depletion contributes to the consistent association between short interpregnancy intervals and fetal growth restriction. One could argue that the evidence is suffi cient to carry through universal postpartum supplementation -also for the maternal benefi t of quick and adequate restoration of folate stores. However, given the current debate on the longer term benefi ts and risks of folic acid supplementation in pregnancy, 47 caution is warranted. Only prospective postnatal intervention studies that also include other relevant outcome measures (such as preterm delivery) can provide decisive evidence in this regard. Meanwhile, one should keep in mind that primary prevention of the interpregnancy interval-associated risks still rests on family planning education, for which the best window of opportunity may lie in the early postnatal period -a critical stage for identifying those women who, intentionally or unintentionally, are most likely to have a short interpregnancy interval. 
